Live webinar: Value demonstration for market access – the new landscape
This webinar is the second in a series of webinars focused on the topic: Unlocking the value; the economic equation. It is also part of the IMS Health Practical Insights series.
Even if your new chemical entity has a patient population which justifies a gold standard RCT, the evidence generated against placebo and key comparators may no longer be enough to deliver access. Indeed, in many cases it is no longer ethical to conduct a placebo-controlled trial.
In the drive to fully understand the value of new treatments, payers increasingly require a full network meta-analysis, demonstrating efficacy against all drugs within the target therapy area. This webinar will deliver real world examples of how mixed treatment and indirect comparison modelling can and should be used to demonstrate value and how to build them into a successful access strategy.
Topics covered include:
- Why the classic RCT is no longer sufficient in today's HTA environment
- Requirements for more extensive comparator data – what, where and how
- The challenges in comparator data from disparate sources
- Key learnings in developing a robust NDA – current challenges and future opportunities
- Learnings from global markets
- Recent case studies – successes and failures
The discussion takes place on Thursday 21 April 2016 at 14.00 BST (09.00 EDT). To reserve your place, please click here or on the button below.
Speakers to be announced shortly.
